Body Part, Organ, or Organ Component
FDA Approves Servier’s Brain Cancer Drug, Triggering $1 Billion Payout for Agios
FDA approval, Servier, brain cancer drug, Voranigo, Agios Pharmaceuticals, IDH1 and IDH2 mutations, blood-brain barrier, cancer metabolism, royalty payments
NGM Bio Secures $122 Million in Funding After Going Private
NGM Bio, funding, private, Column Group, pipeline, orphan diseases
VC Firm Oversees NGM Bio’s $122M Series A Funding After Taking it Private
NGM Bio, The Column Group, Venture Capital, Biotech, Series A Funding
iOnctura Secures €80 Million in Series B Financing to Advance Rare Eye Cancer Treatment
iOnctura, Series B financing, rare eye cancer, uveal melanoma, roginolisib, cancer treatment
Syntis Bio Launches Revolutionary Oral Therapy to Mimic Weight-Loss Surgery
Syntis Bio, weight-loss surgery, oral therapy, obesity, diabetes, rare diseases, SYNT-101, gastric bypass surgery, small intestine, metabolic control, digestion, drug absorption.
Amber Therapeutics Raises $100M for Closed-Loop Neuromodulation Implant for Urinary Incontinence
Amber Therapeutics, urinary incontinence, neuromodulation, closed-loop implant, funding, series A round, pelvic pudendal nerve, mixed incontinence, U.S. regulatory approval.
Biomea’s Early-Stage Diabetes Drug Placed on Full Clinical Hold, Stock Plummets
Biomea, diabetes, clinical hold, FDA, BMF-219, liver toxicity, stock crash
Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy
Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.
Ozempic Reduces Mortality Risk by 20% in Diabetes Patients with Chronic Kidney Disease
** Ozempic, Novo Nordisk, diabetes, chronic kidney disease, mortality risk, cardiovascular deaths, kidney failure, semaglutide, Wegovy, obesity treatment
Tango Pauses Clinical Trials of Promising Solid Tumor Treatment Due to Liver Toxicity Concerns
Tango Therapeutics, solid tumor treatment, clinical trials, liver toxicity, drug development, cancer research, treatment side effects, patient safety.